By Meredith Landry, Managing Editor Of Custom Content, Citeline As drug-device combination products, diagnostics, and digital therapeutics expand, pharma and biotech companies are facing growing materiovigilance demands. Based on IQVIA’s 2025 Materiovigilance and Technology Adoption survey, this report explores how organizations are addressing gaps in safety expertise, processes, and technology while adapting to evolving global regulations.